Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rociletinib
- Development stage
- Discontinued
- Lead developer
- Clovis Oncology
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Rociletinib is an orally available, small molecule, third-generation tyrosine kinase inhibitor (TKI) that irreversibly inhibits the epidermal growth factor receptor (EGFR), specifically targeting both common activating mutations (L858R, Del19) and the T790M resistance mutation in EGFR. It was developed for the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations who have progressed on prior EGFR-targeted therapies. Rociletinib demonstrated antitumor activity in clinical trials but was associated with notable adverse effects such as hyperglycemia and QT prolongation. Development was discontinued after regulatory review due to concerns over efficacy and safety[2][4][5][6].
- Brand names
- Xegafri
- Other names
- rociletinibCO1686CO-1686CO 1686
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on rociletinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rociletinib.